Emily W Gower1, James F Lovato2, Walter T Ambrosius2, Emily Y Chew3, Ronald P Danis4, Matthew D Davis4, David C Goff5, Craig M Greven6. 1. Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Ophthalmology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Electronic address: egower@unc.edu. 2. Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina. 3. National Eye Institute, National Institutes of Health, Bethesda, Maryland. 4. Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin. 5. Department of Epidemiology, University of Colorado School of Medicine, Aurora, Colorado. 6. Department of Ophthalmology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Abstract
PURPOSE: To report the longitudinal association between use of thiazolidinediones (TZDs), visual acuity (VA) change, and diabetic eye disease incidence and progression. DESIGN: Cohort study ancillary to a randomized clinical trial. METHODS: We analyzed baseline and 4-year follow-up data of 2856 ACCORD trial participants with no history of proliferative diabetic retinopathy. Based on stereoscopic fundus photographs, we evaluated diabetic macular edema (DME) progression and DR progression. We also evaluated 10- and 15-letter change on the ETDRS visual acuity chart. Main outcome measures were incidence or progression of DME or DR and change in visual acuity. RESULTS:TZD use was not associated with DME incidence in either the analysis of any use (adjusted odds ratio [aOR] [95% CI]: 1.22 [0.72-2.05]) or duration of use (aOR: 1.02 [0.99-1.04]). Diabetic retinopathy (DR) incidence/progression was more common in patients with no or mild DR at baseline who were ever treated with TZDs (aOR: 1.68 [1.11-2.55]), but this association disappeared when adjusting for the time on TZD (aOR: 1.02 [1.00-1.04]). DR progression among those with moderate or worse DR at baseline was no different between TZD users and non-users. TZD usage had no effect on the ultimate visual acuity outcome. CONCLUSION: In this longitudinal study of patients with type 2 diabetes, we found no association between TZD use and visual acuity outcomes or DME progression, and no consistent evidence of increased DR progression in patients ever treated with TZDs vs those never treated with TZDs.
RCT Entities:
PURPOSE: To report the longitudinal association between use of thiazolidinediones (TZDs), visual acuity (VA) change, and diabetic eye disease incidence and progression. DESIGN: Cohort study ancillary to a randomized clinical trial. METHODS: We analyzed baseline and 4-year follow-up data of 2856 ACCORD trial participants with no history of proliferative diabetic retinopathy. Based on stereoscopic fundus photographs, we evaluated diabetic macular edema (DME) progression and DR progression. We also evaluated 10- and 15-letter change on the ETDRSvisual acuity chart. Main outcome measures were incidence or progression of DME or DR and change in visual acuity. RESULTS:TZD use was not associated with DME incidence in either the analysis of any use (adjusted odds ratio [aOR] [95% CI]: 1.22 [0.72-2.05]) or duration of use (aOR: 1.02 [0.99-1.04]). Diabetic retinopathy (DR) incidence/progression was more common in patients with no or mild DR at baseline who were ever treated with TZDs (aOR: 1.68 [1.11-2.55]), but this association disappeared when adjusting for the time on TZD (aOR: 1.02 [1.00-1.04]). DR progression among those with moderate or worse DR at baseline was no different between TZD users and non-users. TZD usage had no effect on the ultimate visual acuity outcome. CONCLUSION: In this longitudinal study of patients with type 2 diabetes, we found no association between TZD use and visual acuity outcomes or DME progression, and no consistent evidence of increased DR progression in patients ever treated with TZDs vs those never treated with TZDs.
Authors: Ronald E Gangnon; Matthew D Davis; Larry D Hubbard; Lloyd M Aiello; Emily Y Chew; Frederick L Ferris; Marian R Fisher Journal: Invest Ophthalmol Vis Sci Date: 2008-06-06 Impact factor: 4.799
Authors: Walter T Ambrosius; Ronald P Danis; David C Goff; Craig M Greven; Hertzel C Gerstein; Robert M Cohen; Matthew C Riddle; Michael E Miller; John B Buse; Denise E Bonds; Kevin A Peterson; Yves D Rosenberg; Letitia H Perdue; Barbara A Esser; Lea A Seaquist; James V Felicetta; Emily Y Chew Journal: Arch Ophthalmol Date: 2010-03
Authors: Edwin H Ryan; Dennis P Han; Robert C Ramsay; Herbert L Cantrill; Steven R Bennett; Sundeep Dev; David F Williams Journal: Retina Date: 2006 May-Jun Impact factor: 4.256
Authors: Emily Y Chew; Walter T Ambrosius; Matthew D Davis; Ronald P Danis; Sapna Gangaputra; Craig M Greven; Larry Hubbard; Barbara A Esser; James F Lovato; Letitia H Perdue; David C Goff; William C Cushman; Henry N Ginsberg; Marshall B Elam; Saul Genuth; Hertzel C Gerstein; Ulrich Schubart; Lawrence J Fine Journal: N Engl J Med Date: 2010-06-29 Impact factor: 91.245
Authors: David C Goff; Hertzel C Gerstein; Henry N Ginsberg; William C Cushman; Karen L Margolis; Robert P Byington; John B Buse; Saul Genuth; Jeffrey L Probstfield; Denise G Simons-Morton Journal: Am J Cardiol Date: 2007-04-12 Impact factor: 2.778
Authors: John B Buse; J Thomas Bigger; Robert P Byington; Lawton S Cooper; William C Cushman; William T Friedewald; Saul Genuth; Hertzel C Gerstein; Henry N Ginsberg; David C Goff; Richard H Grimm; Karen L Margolis; Jeffrey L Probstfield; Denise G Simons-Morton; Mark D Sullivan Journal: Am J Cardiol Date: 2007-04-16 Impact factor: 2.778
Authors: Emily Y Chew; Walter T Ambrosius; Letitia T Howard; Craig M Greven; Samantha Johnson; Ronald P Danis; Matthew D Davis; Saul Genuth; Michael Domanski Journal: Am J Cardiol Date: 2007-04-13 Impact factor: 2.778
Authors: Tiansheng Wang; Jin-Liern Hong; Emily W Gower; Virginia Pate; Seema Garg; John B Buse; Til Stürmer Journal: Diabetes Care Date: 2018-07-16 Impact factor: 19.112
Authors: Paulina Escandon; Brenda Vasini; Amy E Whelchel; Sarah E Nicholas; H Greg Matlock; Jian-Xing Ma; Dimitrios Karamichos Journal: Exp Eye Res Date: 2021-05-16 Impact factor: 3.770